190 related articles for article (PubMed ID: 18439591)
1. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome.
Brennan K; Huang A; Azziz R
Fertil Steril; 2009 May; 91(5):1848-52. PubMed ID: 18439591
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
Kumar A; Woods KS; Bartolucci AA; Azziz R
Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
[TBL] [Abstract][Full Text] [Related]
3. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
4. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
5. Role of the follistatin gene in women with polycystic ovary syndrome.
Calvo RM; Villuendas G; Sancho J; San Millán JL; Escobar-Morreale HF
Fertil Steril; 2001 May; 75(5):1020-3. PubMed ID: 11334920
[TBL] [Abstract][Full Text] [Related]
6. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
7. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
8. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
Ezeh U; Ezeh C; Pisarska MD; Azziz R
Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
[TBL] [Abstract][Full Text] [Related]
9. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
11. Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome.
Cinar N; Cetinozman F; Aksoy DY; Elcin G; Yildiz BO
J Eur Acad Dermatol Venereol; 2015 May; 29(5):875-80. PubMed ID: 25176476
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
13. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
14. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome.
Farah-Eways L; Reyna R; Knochenhauer ES; Bartolucci AA; Azziz R
Fertil Steril; 2004 Jan; 81(1):120-5. PubMed ID: 14711554
[TBL] [Abstract][Full Text] [Related]
15. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
Sanke S; Chander R; Jain A; Garg T; Yadav P
JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
[TBL] [Abstract][Full Text] [Related]
18. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
19. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
Vermeulen A; Kaufman JM; Giagulli VA
J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
[TBL] [Abstract][Full Text] [Related]
20. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
